Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Gains from Investment Securities (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Gains from Investment Securities data on record, last reported at $1.6 million in Q3 2025.

  • For Q3 2025, Gains from Investment Securities rose 700.27% year-over-year to $1.6 million; the TTM value through Sep 2025 reached $1.6 million, up 75.11%, while the annual FY2025 figure was -$3000.0, 100.07% down from the prior year.
  • Gains from Investment Securities reached $1.6 million in Q3 2025 per CTNM's latest filing, up from $1.1 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $4.1 million in Q2 2024 and bottomed at -$5000.0 in Q1 2023.
  • Average Gains from Investment Securities over 3 years is $1.1 million, with a median of $822500.0 recorded in 2023.
  • The widest YoY moves for Gains from Investment Securities: up 2440.0% in 2024, down 73.26% in 2024.
  • A 3-year view of Gains from Investment Securities shows it stood at $602000.0 in 2023, then soared by 73.26% to $1.0 million in 2024, then skyrocketed by 53.46% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $1.6 million in Q3 2025, $1.1 million in Q1 2025, and $1.0 million in Q4 2024.